CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?

Soon Kyu Lee, Jung Hyun Kwon

Clin Mol Hepatol. 2023;29(3):825-827. Published online 2023 May 31 DOI: https://doi.org/10.3350/cmh.2023.0185

HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?

Soon Kyu Lee, Jung Hyun Kwon

Clinical and Molecular Hepatology. 2023;29(3):825-827

Link1

Link2 Link3

Peripheral and intrahepatic virological phenotyping in HBeAg negative Chronic Hepatitis B to evaluate risk of disease progression and HCC in the “grey-zone” viral load cohort: Can grey-zone patients be candidate to treatment?

R. Salpini, L. Colagrossi, A. Battisti, N. Hansi, C.F. Perno, U.S. Gill, P.T.F. Kennedy, V. Svicher

Digestive and Liver Disease. 2017;49(1):e7

Link1 Link2

Reperfusion Is Delayed Beyond Guideline Recommendations in Patients Requiring Interhospital Helicopter Transfer for Treatment of STEMI

Alberto Perez, James Suozzi, Richard A. Kamin

Annals of Emergency Medicine. 2011;58(6):575-576

Link1 Link2

Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients

Hui Ma, Rui-feng Yang, Lai Wei

Journal of Gastroenterology and Hepatology. 2010;25(9):1498-1506

Link1 Link2

HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis

Tongjing Xing, Hongtao Xu, Lin Cao, Maocong Ye

PLOS ONE. 2017;12(1):e0169444

Link1

Liver Inflammation and Fibrosis of HBeAg-Negative Patients in the Grey Zone

Renling Yao, Jian Wang, Jie Wei, Xiaomin Yan, Yuxin Chen, Juan Xia, Yue Yang, Kefang Yao, Weihua Wu, Yong Liu, Jiacheng Liu, Zhaoping Zhang, Weimao Ding, Rui Huang, Chao Wu

. 2020;

Link1 Link2

Association of Dyslipidemia With Nucleoside Analogue Treatment in HBeAg-Positive Chronic Hepatitis B Patients

Ziqiang Xia, Juzeng Zheng, Liang Zheng, Endian Zheng, Zhuolin Zou, Xiong Sheng, Jinming Wu

. 2021;

Link1 Link2

1031 DURABILITY OF PEGINTERFERON ALFA-2B TREATMENT BEYOND 5 YEARS IN PATIENTS WITH HEPATITIS B E ANTIGEN (HBEAG) POSITIVE CHRONIC HEPATITIS B

V.W.-S. Wong, G.L.-H. Wong, K.K.-L. Yan, A.M.-L. Chim, H.-Y. Chan, H.L.-Y. Chan

Journal of Hepatology. 2010;52:S399

Link1 Link2

On-treatment HBV DNA level could predict HBeAg seroclearance in patients with HBeAg-positive chronic hepatitis B with entecavir therapy

Yi-Jie Huang, Chi-Sen Chang, Yen-Chun Peng, Hong-Zen Yeh, Sheng-Shun Yang

Journal of the Chinese Medical Association. 2017;80(6):341-346

Link1 Link2 Link3

Treatment of heterosexual and homosexual patients with HBeAG positive chronic hepatitis B with low dose interferon alpha (IFN-A)

Journal of Hepatology. 1987;5:S170

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Clin Mol Hepatol has participated in CrossRef Text and Data Mining service since March 1, 2015.